Oral antiviral may cut risk of COVID-19 hospitalisationby nearly 90%, manufacturer claims
Pharmaceutical Journal
; 307(7955), 2022.
Article
in English
| EMBASE | ID: covidwho-2065008
Keywords
antiviral therapy; article; coronavirus disease 2019/dt [Drug Therapy]; hospitalization; human; infection risk; Medicines and Healthcare products Regulatory Agency; phase 2 clinical trial (topic); phase 3 clinical trial (topic); proteinase inhibition; randomized controlled trial (topic); antivirus agent/dt [Drug Therapy]; antivirus agent/po [Oral Drug Administration]; nirmatrelvir plus ritonavir; proteinase/ec [Endogenous Compound]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Language:
English
Journal:
Pharmaceutical Journal
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS